Drug Profile
Cancer vaccine - Metacine
Alternative Names: Dendritic cell cancer vaccine - MetacineLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator University of Pittsburgh
- Developer Metacine; University of Pittsburgh
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Malignant melanoma
Most Recent Events
- 04 Apr 2003 No development reported - Phase-I for Malignant melanoma in USA (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 13 Mar 2001 New profile